Previous 10 | Next 10 |
NEW YORK , March 13, 2019 /PRNewswire/ -- OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market company presentations at the 31 st Annual ROTH Con...
GARDEN CITY, N.Y., and REHOVOT, Israel, March 13, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including ...
AIT Therapeutics ( OTCQB:AITB ): Q3 GAAP EPS of $0.11 beats by $0.64. More news on: AIT Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Announced transformational partnership agreement with Circassia Pharmaceuticals PMA filing for treatment of PPHN on track for second quarter calendar 2019 Completed treatment safely of a compassionate use NTM patient at 250 ppm nitric oxide Strengthened team wi...
GARDEN CITY, N.Y. and REHOVOT, Israel, Feb. 11, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including se...
NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pul...
Milestone payment triggered by successful completion of a pre-submission meeting with the FDA AIT has received $10.5 million to date in upfront and milestone payments PMA submission on track for the second quarter of 2019 GARDEN CITY, N.Y. and REHOVOT, Israel, Feb. 04, 2019 ...
Government and Regulatory China has given the green light to a new registration-based Shanghai stock exchange aimed at high tech companies that, apparently, will be less regulated than other China exchanges. The new exchange is described as resembling NASDAQ with its dealer-to-dealer prici...
Venture Market News for January 24, 2019 AIT Enters into $32.5 million Commercial Licensing Agreement with Circassia Pharmaceuticals for Its Novel Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and China Additionally, AIT to garner a 15%...
Additionally, AIT to garner a 15%-20% royalty on gross profit AIT will immediately request to be listed on the NASDAQ stock exchange PMA submission on track for the second quarter of 2019 Company to host a call today, Thursday, January 24, 2019 at 8:30am ET GARDEN CITY, N.Y...
News, Short Squeeze, Breakout and More Instantly...
AIT Therapeutics Inc Company Name:
AITB Stock Symbol:
OTCMKTS Market:
Announces name change to Beyond Air™ Completed uplisting to the NASDAQ and $7.96 million PIPE financing Anticipate PMA submission in the third quarter of calendar 2019 Anticipate CE Mark in the first half of calendar 2020 Announced licensing agreement ...
Announces name change to Beyond Air™ Completed uplisting to the NASDAQ and $7.96 million PIPE financing Anticipate PMA submission in the third quarter of calendar 2019 Anticipate CE Mark in the first half of calendar 2020 Announced licensing agreeme...
GARDEN CITY, N.Y. and REHOVOT, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including s...